Evoxac and Respiratory disorder - a phase IV clinical study of FDA data

Summary:

Respiratory disorder is reported as a side effect among people who take Evoxac (cevimeline hydrochloride), especially for people who are female, 60+ old, also take Pravachol, and have Osteoporosis.

The phase IV clinical study analyzes which people have Respiratory disorder when taking Evoxac. It is created by eHealthMe based on reports of 1,960 people who have side effects when taking Evoxac from the FDA, and is updated regularly.

What is Evoxac?

Evoxac has active ingredients of cevimeline hydrochloride. It is often used in sjogren syndrome. eHealthMe is studying from 2,028 Evoxac users. Check the latest studies of Evoxac.

What is Respiratory disorder?

Respiratory disorder (respiratory disease) is found to be associated with 1,535 drugs and 1,584 conditions by eHealthMe. Check the latest studies of Respiratory disorder.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

1,960 people reported to have side effects when taking Evoxac.
Among them, 30 people (1.53%) have Respiratory disorder.

Could Evoxac cause Respiratory disorder?

Among these 30 people:

What is the gender of people who have Respiratory disorder when taking Evoxac? *

female: 86.67 %
male: 13.33 %

What is the age of people who have Respiratory disorder when taking Evoxac? *

What are other drugs people take besides Evoxac? *

What are other side effects people have besides Respiratory disorder? *

Heart Rate Irregular: 24 people, 80.00%
Dyspnea (difficult or laboured breathing): 24 people, 80.00%
Diarrhea: 24 people, 80.00%
Osteopenia (a condition where bone mineral density is lower than normal): 23 people, 76.67%
Ear Barotrauma (discomfort and possible damage in the ear due to pressure differences between the inside and outside of the eardrum): 23 people, 76.67%
Osteomyelitis (infection of bone): 23 people, 76.67%
Osteolysis (dissolution of bone): 23 people, 76.67%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 23 people, 76.67%
High Blood Pressure: 23 people, 76.67%
Oropharyngeal Pain: 23 people, 76.67%

What are the existing conditions these people have? *

Osteoporosis (bones weak and more likely to break): 23 people, 76.67%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 10.00%
Anaemia (lack of blood): 2 people, 6.67%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 2 people, 6.67%
Pain: 2 people, 6.67%
Type 2 Diabetes: 1 person, 3.33%
Hepatic Function Abnormal: 1 person, 3.33%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 3.33%
B Precursor Type Acute Leukaemia (lymphoid cancer): 1 person, 3.33%
Colitis (inflammation of colon): 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Evoxac and have Respiratory disorder?

- Check whether Respiratory disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Evoxac:

Evoxac (2,028 reports)

Browse all side effects of Evoxac:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Respiratory disorder:

Respiratory disorder (1,535 drugs)

Browse all the conditions that are associated with Respiratory disorder:

Respiratory disorder (1,584 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cevimeline hydrochloride (the active ingredients of Evoxac) and Evoxac (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.